Skip to main content

Table 4 Eligibility for Short Course Regimen by Clinical Criteria and DST Performed. c. Participants with Pulmonary MDR-TB Eligible for Short Course Treatment with < 1 Month of MDR-TB Treatment, by DST Performed

From: Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic

Resistance Status Xpert Only, N = 175 2nd-Line LPA Only,a N = 146 Testing R, FQ, INJ, Z, and E, N = 140b Testing R, FQ, INJ, Z, E, Eto, and Cfz, N = 136b
  # Eligible or Resistant / # Tested (%)c # Eligible or Resistant / # Tested (%)c # Eligible or Resistant / # Tested (%)c # Eligible or Resistant / # Tested (%)c
Eligible for Short Course 175 / 175 (100) 46 / 146 (31.5) 9 / 140 (6.4) 8 / 136 (5.9)
Resistant to FQ or INJ N/A 100 / 146 (68.5) 95 / 140 (67.9) 93 / 136 (68.4)
Resistant to Z or E N/A N/A 128 / 140 (91.4) 124 / 136 (91.2)
Resistant to FQ, INJ, Z, or E N/A N/A 131 / 140 (93.6) 127 / 136 (93.4)
Resistant to FQ, INJ, Z, E, Eto, or Cfz N/A N/A N/A 128 / 136 (94.1)
  1. a2nd-line LPA tests for susceptibility to isoniazid, rifampin, fluoroquinolones, and 2nd-line injectables (amikacin, capreomycin, or kanamycin)
  2. bR rifampin, FQ fluoroquinolone, INJ 2nd-line injectable, Z pyrazinamide, E ethambutol, Eto ethionamide, Cfz clofazimine
  3. cPercentages reported reflect number of participants with resistance or susceptibility divided by number of participants who completed susceptibility testing for each drug. As a result, the number of participants in the denominator is not the same in all rows